These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7318237)

  • 1. The influence of 8-methoxypsoralen plus UV-A (PUVA) on the excretion of the main urinary metabolite of prostaglandins F 1 alpha and F 2 alpha in patients with psoriasis.
    Briffa DV; Greaves MW; Hensby CN
    Clin Exp Dermatol; 1981 Sep; 6(5):471-6. PubMed ID: 7318237
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduced excretion of the main urinary metabolite of prostaglandin F1 alpha and F2 alpha in psoriatic patients.
    Katayama H; Kawada A; Endoh C; Hori H; Yoshikawa K
    Acta Derm Venereol; 1983; 63(3):233-5. PubMed ID: 6192638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of ultraviolet B irradiation on the excretion of the main urinary metabolite of prostaglandin F1 alpha and F2 alpha in psoriatic and normal subjects.
    Katayama H; Hori H
    Acta Derm Venereol; 1984; 64(1):1-4. PubMed ID: 6203274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of main urinary metabolite of PGFs in chronic lung diseases.
    Murao M; Uchiyama K; Takahashi W; Hirata F; Inagawa T
    Adv Prostaglandin Thromboxane Res; 1980; 7():965-8. PubMed ID: 7369061
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolism of PG in man: effect of furosemide on the excretion of the main metabolite of PG F2alpha.
    Abe K; Otsuka Y; Yasujima M; Ciba S; Seino M; Irokawa N; Yoshinaga K
    Prostaglandins; 1976 Nov; 12(5):843-8. PubMed ID: 981707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The identification of 5beta,7alpha-dihydroxy-11-oxotetranor-prostane-1,16-dioic acid as a urinary metabolite of prostaglandin F2alpha in the rat.
    Brash AR; Baillie TA
    Biochim Biophys Acta; 1979 Feb; 572(2):371-5. PubMed ID: 427184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary excretion of 6-hydroxy-5-methoxyindole-2-carboxylic acid and 5-S-cysteinyldopa during PUVA treatment.
    Hansson C; Wirestrand LE; Aronsson A; Rorsman H; Rosengren E
    Photodermatol; 1985 Apr; 2(2):52-7. PubMed ID: 3929237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical 8-methoxypsoralen photochemotherapy of psoriasis: a clinical study.
    Danno K; Horio T; Ozaki M; Imamura S
    Br J Dermatol; 1983 May; 108(5):519-24. PubMed ID: 6342648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of phototherapy (UV-B) and photochemotherapy (PUVA) for clearing and maintenance therapy of psoriasis.
    Boer J; Hermans J; Schothorst AA; Suurmond D
    Arch Dermatol; 1984 Jan; 120(1):52-7. PubMed ID: 6691715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral 8-methoxypsoralen photochemotherapy in psoriasis.
    Nozicková-Novotná M
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1983; 26(5):545-77. PubMed ID: 6599175
    [No Abstract]   [Full Text] [Related]  

  • 11. Psoralens and UV-A and UV-B twice weekly for the treatment of psoriasis.
    Diette KM; Momtaz-T K; Stern RS; Arndt KA; Parrish JA
    Arch Dermatol; 1984 Sep; 120(9):1169-73. PubMed ID: 6476854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between plasma levels of 8-methoxypsoralen and skin photosensitivity: the interest of pharmacokinetic studies during photochemotherapy of psoriasis.
    Beani JC; Sarrazin C; Amblard P; Reymond JL; Beriel H; Boitard M
    Dermatologica; 1983; 166(4):169-74. PubMed ID: 6852331
    [No Abstract]   [Full Text] [Related]  

  • 13. The importance of patient selection for photochemotherapy in psoriasis.
    DesGroseilliers JP; Reilly SM; Cullen AE
    Can Med Assoc J; 1981 Apr; 124(8):1016-8. PubMed ID: 7260785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma 8-methoxypsoralen concentrations in photochemotherapy of psoriasis.
    Stevenson IH; Kenicer KJ; Johnson BE; Frain-Bell W
    Br J Dermatol; 1981 Jan; 104(1):47-51. PubMed ID: 7459268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a homologous internal standard for the quantification of the major metabolite of prostaglandin F2 alpha in human urine by multiple ion analysis.
    Ferretti A; Flanagan VP; Roman JM
    Anal Biochem; 1984 Jan; 136(1):217-22. PubMed ID: 6711810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of oral methoxypsoralen: photochemotherapy (PUVA) and an aromatic retinoid (etretinate, tigason) in the treatment of psoriasis.
    Thirumoorthy T; Tham SN; Tan YC
    J Dermatol; 1986 Apr; 13(2):132-6. PubMed ID: 3531270
    [No Abstract]   [Full Text] [Related]  

  • 17. Itch following photochemotherapy for psoriasis.
    Rogers S; Marks J; Shuster S
    Acta Derm Venereol; 1981; 61(2):178-80. PubMed ID: 6165204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An assessment of the effect of photochemotherapy (PUVA) and UV-B phototherapy in the treatment of psoriasis.
    Kenicer KJ; Lakshmipathi T; Addo HA; Johnson BE; Frain-Bell W
    Br J Dermatol; 1981 Dec; 105(6):629-39. PubMed ID: 7317277
    [No Abstract]   [Full Text] [Related]  

  • 19. Deuterium- and tritium-labeled (+/-)-7alpha-hydroxy-5,11-diketotetranorprostane-1,16-dioic acid.
    Rosegay A; Taub D
    Prostaglandins; 1976 Nov; 12(5):785-7. PubMed ID: 981702
    [No Abstract]   [Full Text] [Related]  

  • 20. [PUVA therapy: decrease of the 8-methoxypsoralen level following local administration].
    Meffert H; Metz D
    Dermatol Monatsschr; 1980 Aug; 166(8):566-7. PubMed ID: 7461250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.